About Stern Investor Relations
Stern Investor Relations was founded in 1998 to provide biotechnology, healthcare, and pharmaceutical investor relations services.
Stern IR is an investor relations company that seeks to develop longstanding relationships with high-quality firms in all stages of development. We customize each client's investor relations program according to its specific needs and goals. Committed to superior client service, we are proud to provide each client with senior level attention, strategic counsel and critical, disciplined tactical support.
Specialization in Healthcare Investor Relations
The financial markets and the healthcare industry in particular undergo frequent changes. Because of our specific focus on the biotechnology and healthcare industries, we possess an extensive, detailed and up-to-the-minute knowledge of the sector, regulatory issues and the current market environment. We closely monitor industry trends to provide a comprehensive approach to investor relations counsel. Stern is one of the leading investor relations firms focused primarily on biotechnology, healthcare, and pharmaceuticals.
Relationships with the Healthcare Investment Community
As a result of our specialization in the healthcare sector, we have cultivated many valuable relationships within the investment community and know the major players and industry events. We facilitate introductions with crucial contacts on Wall Street and help our clients develop and improve existing relationships. Investor conferences and industry events are an important part of a successful investor relations program, and we leverage our relationships in the industry to target the highest quality events for each client and to help obtain the most value from each event. Through a combination of scientific briefings, analyst meetings and roadshows, we familiarize the financial community with our clients and their corporate messages.
Focus on Best Investor Relations Company Practices
While each client will have its own set of specific goals and subsequent tactics, we believe that high-quality companies should operate their investor relationship management programs according to current best industry practice. We advise our clients accordingly, helping them convey news and information to research analysts and investors regularly and consistently, with special attention to timing, positioning, accuracy and fair disclosure policies. In addition, we provide appropriate guidance to clients to ensure they maintain the respect and trust that is vital to a company's reputation on Wall Street.
Our team of experienced, analytical, investor relations professionals offers a proven track record of delivering results. Years of experience and superior client service allow us to provide sophisticated and critical direction, unique insights and a total perspective to meet clients' needs.
Lilian Stern, Principal and Founder, Stern Investor Relations
Lilian Stern has been a senior investor relations counselor in the biotechnology industry for over 15 years, representing more than 200 companies ranging from start-ups to large-cap public companies, in a broad range of development stages and therapeutic areas. As Principal of Stern IR, she works closely with client teams, providing skilled and knowledgeable IR counsel. Prior to founding Stern IR, Lilian established and ran the investor relations group at Burns McClellan for six years and worked as a biotechnology sell-side analyst at Donaldson, Lufkin & Jenrette/Credit Suisse First Boston. She holds an A.B. with distinction from Cornell University and a J.D. with honors from Harvard Law School.
Our account teams provide each client with senior level counsel and strategic planning as well as full and rigorous tactical support from our superb junior staff. From the top down, we are pleased to offer savvy IR support with an exacting attention to detail.